J Cancer 2020; 11(5):1182-1194. doi:10.7150/jca.37313 This issue

Research Paper

Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma

Lin Fu1,2,3, Zhiheng Cheng4, Fen Dong5, Liang Quan1,2, Longzhen Cui6, Yan Liu6, Tiansheng Zeng7, Wenhui Huang1,2, Jinghong Chen2, Ying Pang1, Xu Ye1, Guangsheng Wu8, Tingting Qian1,2✉, Yang Chen9✉, Chaozeng Si10✉

1. Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China.
2. Translational Medicine Center, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
3. Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, China.
4. Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
5. Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, 100029, China.
6. Translational Medicine Center, Huaihe Hospital of Henan University, Kaifeng, China.
7. Department of Biomedical Sciences, University of Sassari, Sassari, 07100, Italy.
8. Department of Hematology, First Affiliated Hospital, Medical College of Shihezi University, Shihezi 832008, China.
9. MOE Key Laboratory of Bioinformatics; Bioinformatics Division and Center for Synthetic & Systems Biology, TNLIST; Department of Automation, Tsinghua University, Beijing, 100084, China.
10. Department of Operations and Information Management, China-Japan Friendship Hospital, Beijing, 100029, China.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Fu L, Cheng Z, Dong F, Quan L, Cui L, Liu Y, Zeng T, Huang W, Chen J, Pang Y, Ye X, Wu G, Qian T, Chen Y, Si C. Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma. J Cancer 2020; 11(5):1182-1194. doi:10.7150/jca.37313. Available from https://www.jcancer.org/v11p1182.htm

File import instruction

Abstract

Background: Multiple myeloma (MM) is the second most common hematologic malignancy worldwide and does not have sufficient prognostic indicators. FCER1G (Fc fragment Of IgE receptor Ig) is located on chromosome 1q23.3 and is involved in the innate immunity. Early studies have shown that FCER1G participates in many immune-related pathways encompassing multiple cell types. Meanwhile, it is associated with many malignancies. However, the relationship between MM and FCER1G has not been studied.

Methods: In this study, we integrated nine independent gene expression omnibus (GEO) datasets and analyzed the associations of FCER1G expression and myeloma progression, ISS stage, 1q21 amplification and survival in 2296 myeloma patients and 48 healthy donors.

Results: The expression of FCER1G showed a decreasing trend with the advance of myeloma. As ISS stage and 1q21 amplification level increased, the expression of FCER1G decreased (P = 0.0012 and 0.0036, respectively). MM patients with high FCER1G expression consistently had longer EFS and OS across three large sample datasets (EFS: P = 0.0057, 0.0049, OS: P = 0.0014, 0.00065, 0.0019 and 0.0029, respectively). Meanwhile, univariate and multivariate analysis indicated that high FCER1G expression was an independent favorable prognostic factor for EFS and OS in MM patients (EFS: P = 0.006, 0.027, OS: P =0.002,0.025, respectively).

Conclusions: The expression level of FCER1G negatively correlated with myeloma progression, and high FCER1G expression may be applied as a favorable biomarker in MM patients.

Keywords: Multiple myeloma, FCER1G, Prognosis, Gene expression profile, Bioinformatics analysis